首页> 美国卫生研究院文献>Oncotarget >The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies
【2h】

The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies

机译:循环肿瘤细胞在膀胱癌和上尿路尿路上皮癌中的预后和诊断价值:对30篇发表的研究的荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

There are inconsistent conclusions in the association between circulating tumor cells (CTCs) and urothelial cancer (UC). We performed a meta-analysis to assess the prognostic and diagnostic value of CTCs in UC. We search Medline, Embase and Web of science for relevant studies. The study was set up according to the inclusion/exclusion criteria. 30 published studies with a total of 2161 urothelial cancer patients were included. Meta-analysis showed that CTC-positive was significantly associated with tumor stage (≤ II vs III, IV) (OR = 4.60, 95% CI: 2.34–9.03), histological grade (I, II vs III) (OR = 2.91, 95% CI: 1.92–4.40), metastasis (OR = 5.12, 95% CI: 3.47–7.55) and regional lymph node metastasis (OR = 2.47, 95% CI: 1.75–3.49). It was also significantly associated with poor overall survival (OS) (HR = 3.98, 95% CI: 2.20–7.21), progression/disease-free survival (PFS/DFS) (HR = 2.22, 95% CI: 1.80–2.73) and cancer-specific survival (CSS) (HR = 5.18, 95% CI: 2.21–12.13). Overall sensitivity and specificity of CTC detection assays were 0.35 (95% CI: 0.28–0.43) and 0.97 (95% CI: 0.92–0.99) respectively. In summary, our meta-analysis suggests that the presence of CTCs in the peripheral blood is an independent predictive indicator of poor outcomes for urothelial cancer patients. It can also be used as a noninvasive method for the confirmation of cancer diagnosis. More studies are required to further explore the role of this marker in clinical practice.
机译:关于循环肿瘤细胞(CTC)和尿路上皮癌(UC)之间的关联,存在不一致的结论。我们进行了荟萃分析,以评估UC中CTC的预后和诊断价值。我们在Medline,Embase和Web of Science中搜索相关研究。根据纳入/排除标准建立研究。纳入了30篇公开研究,总共2161名尿路上皮癌患者。荟萃分析显示,CTC阳性与肿瘤分期(≤II vs III,IV)(OR = 4.60,95%CI:2.34-9.03),组织学分级(I,II vs III)显着相关(OR = 2.91, 95%CI:1.92–4.40),转移(OR = 5.12,95%CI:3.47–7.55)和区域淋巴结转移(OR = 2.47,95%CI:1.75–3.49)。它也与不良总生存期(OS)(HR = 3.98,95%CI:2.20–7.21),无进展/无疾病生存期(PFS / DFS)(HR = 2.22,95%CI:1.80–2.73)显着相关。和癌症特异性生存(CSS)(HR = 5.18,95%CI:2.21–12.13)。 CTC检测测定的总体敏感性和特异性分别为0.35(95%CI:0.28-0.43)和0.97(95%CI:0.92-0.99)。总之,我们的荟萃分析表明,外周血中CTC的存在是尿路上皮癌患者预后不良的独立预测指标。它也可以用作确认癌症诊断的非侵入性方法。需要更多的研究来进一步探索该标志物在临床实践中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号